Extended Data Fig. 1: Trial design. | Nature Medicine

Extended Data Fig. 1: Trial design.

From: A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial

Extended Data Fig. 1

The trial design of a phase 1b study in patients with ESCC populations. ESCC, esophageal squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group; RECIST, Response Evaluation Criteria in Solid Tumors; RP2D, recommended phase 2 dose; ORR, objective response rate; DCR, disease control rate; DOR, duration of response; PK, pharmacokinetic; ADA, anti-drug antibodies; PFS, progression-free survival; OS, overall survival.

Back to article page